Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1977-9-17
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0090-466X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
5
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
193-205
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:881641-Administration, Oral,
pubmed-meshheading:881641-Adult,
pubmed-meshheading:881641-Alprenolol,
pubmed-meshheading:881641-Biological Availability,
pubmed-meshheading:881641-Female,
pubmed-meshheading:881641-Humans,
pubmed-meshheading:881641-Infusions, Parenteral,
pubmed-meshheading:881641-Male
|
pubmed:year |
1977
|
pubmed:articleTitle |
Importance of "first-pass elimination" for interindividual differences in steady-state concentrations of the adrenergic beta-receptor antagonist alprenolol.
|
pubmed:publicationType |
Journal Article
|